ReviewFrontiers in cardiovascular medicine2021
Gut Microbiota and Atherosclerosis-Focusing on the Plaque Stability.
Review in Frontiers in cardiovascular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 88 citations in OpenAlex.
- Gut Microbiota and Atherosclerotic Plaque Instability: Cellular and Molecular Mechanisms.International journal of molecular sciences · 2026Review
- Association Between Metabolic Clusters and Microbial Age in High-Risk Populations for Diabetes and Their Potential Impact on Cardiovascular Disease Risk: Cross-Sectional Observational Study.JMIR medical informatics · 2026Observational
- Modulation of gut-heart axis by synbiotic (Lactiplantibacillus plantarum M10 and Isomaltose) in high cholesterol diet induced atherosclerotic murine model.BMC microbiology · 2026Article
- Mycotoxins, gut microbiota alterations and liver disease in animals: A scoping review.Cell biology and toxicology · 2026Review
- Multi-Omics Mechanisms of Trimethylamine Oxide and Cardiovascular Disease: A Review.Reviews in cardiovascular medicine · 2026Review
- Intestinal aging-related immune dysfunction: mechanisms and interventions.Acta biochimica et biophysica Sinica · 2026Review
- Article
- Ameliorative effects of mulberry fruit anthocyanin extract on gut microbiota and liver metabolites in high-fat and high-cholesterol diet-fed ApoE-/- mice.Frontiers in nutrition · 2026Article
- Microbiota-Driven Immune Dysregulation Along the Gut-Lung-Vascular Axis in Asthma and Atherosclerosis.Biomedicines · 2025Review
- Gut Microbiota and Atherosclerosis: Integrative Multi-Omics and Mechanistic Insights.Current atherosclerosis reports · 2025Review
- Gut microbiota-cholesterol crosstalk in cardiovascular diseases: mechanisms, metabolites, and therapeutic modulation.Nutrition & metabolism · 2025Review
- Polyphenol-Microbiota Interactions in Atherosclerosis: The Role of Hydroxytyrosol and Tyrosol in Modulating Inflammation and Oxidative Stress.Nutrients · 2025Review
- Selection and potential of cholesterol-lowering indigenous probiotic: insights from in vitro and in vivo study.Scientific reports · 2025Article
- The Efficacy of Hesperidin in the Reduction of Atherosclerosis in ApoEFoods (Basel, Switzerland) · 2025Article
- TMAO and Cardiovascular Disease: Exploring Its Potential as a Biomarker.Medicina (Kaunas, Lithuania) · 2025Review
- Gut Microbiota-Derived Metabolites in Atherosclerosis: Pathways, Biomarkers, and Targets.International journal of molecular sciences · 2025Review
- Microbiome and cardiovascular health unexplored frontiers in precision cardiology: a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Key parameters for designing robust 2D and 3D spheroid models forBioengineering & translational medicine · 2025Review
- Systemic lupus erythematosus and atherosclerosis: immune pathways and the uncharted territory of gut microbiota and metabolism.Frontiers in immunology · 2025Review
- Potential effects of probiotics on atherosclerosis.Microbiome research reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) are major causes of mortality and morbidity in the modern society. The rupture of atherosclerotic plaque can induce thrombus formation, which is the main cause of acute cardiovascular events. Recently, many studies have demonstrated that there are some relationships between microbiota and atherosclerosis. In this review, we will focus on the effect of the microbiota and the microbe-derived metabolites, including trimethylamine-N-oxide (TMAO), short-chain fatty acids (SCFAs), and lipopolysaccharide (LPS), on the stability of atherosclerotic plaque. Finally, we will conclude with some therapies based on the microbiota and its metabolites.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.